217 related articles for article (PubMed ID: 12542480)
1. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.
Abildgaard N; Brixen K; Kristensen JE; Eriksen EF; Nielsen JL; Heickendorff L
Br J Haematol; 2003 Jan; 120(2):235-42. PubMed ID: 12542480
[TBL] [Abstract][Full Text] [Related]
2. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.
Jakob C; Zavrski I; Heider U; Brux B; Eucker J; Langelotz C; Sinha P; Possinger K; Sezer O
Eur J Haematol; 2002 Jul; 69(1):37-42. PubMed ID: 12270060
[TBL] [Abstract][Full Text] [Related]
3. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
4. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma.
Abildgaard N; Glerup H; Rungby J; Bendix-Hansen K; Kassem M; Brixen K; Heickendorff L; Nielsen JL; Eriksen EF
Eur J Haematol; 2000 Feb; 64(2):121-9. PubMed ID: 10997332
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios.
Carlson K; Larsson A; Simonsson B; Turesson I; Westin J; Ljunghall S
Eur J Haematol; 1999 May; 62(5):300-6. PubMed ID: 10359057
[TBL] [Abstract][Full Text] [Related]
6. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.
Abildgaard N; Brixen K; Eriksen EF; Kristensen JE; Nielsen JL; Heickendorff L
Haematologica; 2004 May; 89(5):567-77. PubMed ID: 15136220
[TBL] [Abstract][Full Text] [Related]
7. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
8. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.
Jakob C; Zavrski I; Heider U; Bollow M; Schulz CO; Fleissner C; Eucker J; Michael R; Hamm B; Possinger K; Sezer O
Clin Cancer Res; 2003 Aug; 9(8):3047-51. PubMed ID: 12912955
[TBL] [Abstract][Full Text] [Related]
10. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
11. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma.
Elomaa I; Virkkunen P; Risteli L; Risteli J
Br J Cancer; 1992 Aug; 66(2):337-41. PubMed ID: 1503907
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of biochemical markers in patients with metabolic bone disorders.
Hoshino H; Kushida K; Takahashi M; Kawana K; Denda M; Yamazaki K; Inoue T
Endocr Res; 1998 Feb; 24(1):55-64. PubMed ID: 9553754
[TBL] [Abstract][Full Text] [Related]
14. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic validity of bone metabolic markers for bone metastasis.
Miura H; Yamamoto I; Takada M; Kigami Y; Ohta T; Yuu I; Hamanaka Y; Matsushita R; Morita R
Endocr J; 1997 Oct; 44(5):751-7. PubMed ID: 9466334
[TBL] [Abstract][Full Text] [Related]
17. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
18. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
20. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
